Latest News

Darra, QLD, Australia and Menlo Park, CA USA, June 18, 2017 — Brisbane Materials, a specialty materials company, today announced that the company has closed its Series B Funding. Participants in the round included existing investors New Venture Partners LLC, the...

  June 16, 2017 Melbourne, Victoria – Australian developed medical technology which uses the blood clotting properties of snakes including the Australian Coastal Taipan, one of the world’s deadliest, is set to revolutionise the world of blood testing and assist...

AVCAL feature on Hatchtech featuring CEO Hugh Alsop and University of Melbourne Inventor Professor Vern Bowles. https://vimeo.com/209321812?platform=hootsuite

Melbourne, 7 June 2017 – Uniseed and the MRCF today announced a joint investment of US$16 million in Series A funding for QUE Oncology Incorporated, a clinical stage biotechnology company developing novel cancer supportive care and anticancer therapies, jointly...

Melbourne, Australia, 23 May, 2017 – Innavac Pty Ltd, a biotechnology company spun out of the University of Melbourne that is developing novel, synthetic Toll-like receptor (TLR) agonists as therapies for the prevention and treatment of respiratory infections, has...

               MEDIA RELEASE   Appointment of Experienced Beverage and Marketing Executives to the PERKii Board of Directors Brisbane, Australia, March 13 2017: Uniseed investee company PERKii Pty Ltd, is pleased to announce the appointment of three new Directors...

MEDIA RELEASE   New drugs in development to starve cancer cells Revolutionary new cancer therapies for patients suffering with some of the most difficult-to-treat cancers are now being developed following a major discovery by scientists in the ACRF Centenary Cancer...

Monday 6 March, The Australian Financial...

-     Universities of Melbourne, New South Wales, Sydney and Queensland each commit $5 million to new Uniseed Follow-On Fund; -     Follow-On Fund to focus on lower risk, later stage investment rounds into investee companies. Brisbane, Australia, March 7 2017:...

Auris Medical Expands Clinical Development Pipeline with Intranasal Betahistine for the Treatment of Meniere’s Disease and Vestibular Vertigo - Pipeline strengthens with addition of AM-125 as third clinical-stage program - Acquisition of assets related to innovative...